Nrf2 Polyclonal pAb
- Known as:
- Nrf2 Polyclonal pAb
- Catalog number:
- ASAKAP-TF125F
- Product Quantity:
- 200 µg
- Category:
- -
- Supplier:
- Other suppliers
- Gene target:
- Nrf2 Polyclonal pAb
Related genes to: Nrf2 Polyclonal pAb
- Gene:
- KEAP1 NIH gene
- Name:
- kelch like ECH associated protein 1
- Previous symbol:
- -
- Synonyms:
- KIAA0132, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454, INrf2, KLHL19
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2003-09-30
- Date modifiied:
- 2015-11-23
Related products to: Nrf2 Polyclonal pAb
Related articles to: Nrf2 Polyclonal pAb
- Mitochondrial oxidative stress is a major factor of neurological diseases by generating and accumulating ROS, LPO, and 4-HNE in the brain. Here, cadmium chloride (CdCl2) is injected into mice (5 mg/kg per mouse, I.P.) to establish an animal model and to analyze elevated oxidative stress, neuroinflammation, apoptosis, reduced body weight, and synaptic impairment. The therapeutic agent Cistanoside A (CA) was administered to the CdCl2-treated mice group at a dose of 60 mg/kg per mouse for 4 weeks, P.O. The CdCl2 + CA-treated mice group reversed the elevated levels of ROS, LPO, GSH, and SOD in the mice brain homogenates and improved the levels of endogenous antioxidant biomarkers (Nrf2 and HO-1). Similarly, CA reduced neuroinflammation, as analyzed with GFAP, Iba-1, p-NFKB, IL-1β, and TNF-α in the CdCl2 + CA co-treated group. Furthermore, CA preserved neuronal integrity and morphology in the mouse brain, as analyzed via western blot (i.e., Bax and Bcl2), Nissl staining, Hematoxylin & Eosin staining, and immunohistochemistry. In silico, our therapeutic agent CA shows strong interaction with the active site of Keap-1 and enhances the activity of NRF2 to inhibit CdCl2-induced oxidative stress and downstream signaling. Accumulatively, the therapeutic agent CA (60 mg/kg per mouse) potentially reversed oxidative stress, neuroinflammation, and the progression of neurodegeneration in the mouse CdCl2-injected neurotoxic model. - Source: PubMed
Publication date: 2026/09/01
Ali WaqarAhmad ImadRahman Najeeb UrKhan JawadAlam WaqasRabbi FazleShams BilalRahim TabbasumRehman HarisShams Hamid - Mori Cortex Radicis (MCR) is an important Chinese herbal medicine with antitussive, anti-inflammatory, and analgesic effects. It is abundant in resources and low in cost, but its application in the control of fish pathogens has been insufficiently studied. - Source: PubMed
Publication date: 2026/08/17
Zhang XingZhu LingYu YixinWang KaiHu QinkaiHuang XuanZhu GuangbaoMa JingjingLi ShanshanLiu Xiang - Mesenchymal stem cells (MSCs) hold considerable therapeutic promise in regenerative medicine, yet precise control over lineage fate remains critical for reproducible clinical outcomes. This review examines the Nrf2-Keap1 (nuclear factor erythroid 2-related factor 2-Kelch-like ECH-associated protein 1) signaling axis as a redox-sensitive rheostat governing the balance between osteogenic and adipogenic differentiation. Physiological reactive oxygen species (ROS) support osteogenesis in a dose- and context-dependent manner, whereas sustained oxidative stress drives cellular senescence and adipogenic bias; emerging evidence also indicates that Nrf2 hyperactivation can itself impair osteogenic differentiation, pointing to an optimal activation window rather than a simple "more is better" relationship. Conventional plant-derived Nrf2 activators are limited by poor bioavailability and metabolic stability. Phytofabricated metal oxide nanoparticles (MONPs), synthesized using plant extracts as capping and stabilizing agents, offer a biocompatible, "green" delivery alternative. We propose that these hybrid systems may act through a dual-stimulus mechanism - phytochemical-mediated electrophilic modification of Keap1 cysteines alongside metal-oxide-core-derived, sub-cytotoxic ROS consistent with mitohormetic signaling - that together could promote Nrf2 nuclear translocation, ARE-driven antioxidant gene expression, and downstream epigenetic reinforcement of osteogenic commitment. This dual-stimulus framework, however, remains a mechanistic hypothesis: no study to date has directly demonstrated Keap1 modification, Nrf2 activation, and resulting lineage bias by phytofabricated MONPs within MSCs. Preclinical studies support the efficacy of phytofabricated MONPs in bone defect models and suggest potential for restoring function in senescent MSCs, but direct mechanistic validation in MSC systems remains an essential next step before these insights can guide rational nanoplatform design for bone regeneration. - Source: PubMed
Irfan MuhammadTaha MuhammadAsghar Syed Muhammad FaizanRaza Muhammad - Dendrobium officinale Kimura et Migo is a prestigious traditional Chinese medicine historically used for treating "Xiao-Ke" (diabetes and its complications). However, the specific material basis and direct molecular targets responsible for its efficacy against diabetic cardiomyopathy (DCM) remain largely obscure. This study aimed to systematically investigate whether dendrobine, the characteristic active alkaloid of DO, serves as the principal cardioprotective component by directly targeting the KEAP1-NRF2 signaling axis. - Source: PubMed
Publication date: 2026/08/21
Xiang XiaojueLin XuWu QifangZhang XiaomingFu XueliangWu LinyaTong HaibinDai Zhenyu - Premature ovarian insufficiency (POI) is a heterogeneous disorder characterized by loss of ovarian function before age 40, causing infertility, hypoestrogenism-related complications, and significantly impaired quality of life. Although hormone replacement therapy (HRT) remains the standard treatment for symptom relief and long-term health protection, it cannot restore ovarian reserve or natural fertility. This review summarizes the etiology and pathogenesis of POI, emphasizing mitochondrial dysfunction, oxidative stress, chronic inflammation, and progressive deterioration of the ovarian microenvironment. We critically evaluate the strengths and limitations of conventional HRT based on the latest 2024 international evidence-based guidelines, and comprehensively overview emerging regenerative therapies, focusing on mesenchymal stem cells (MSCs) and MSC-derived small extracellular vesicles (sEVs). MSCs exert therapeutic effects mainly through paracrine actions, including anti-apoptotic, anti-inflammatory, and pro-angiogenic activities. MSC-sEVs, particularly hypoxia-preconditioned ones, offer a safer cell-free alternative. They protect mitochondrial function via the SIRT3/PGC-1α pathway and other related mechanisms such as Nrf2/Keap1 and AMPK signaling. Current clinical evidence for both approaches remains preliminary, consisting mainly of small-scale trials with heterogeneous protocols and short follow-up. We propose an innovative ovarian microenvironment remodeling framework that integrates symptomatic HRT with etiology-targeted regenerative interventions using MSCs or engineered sEVs. In summary, while HRT forms the foundation of POI management, MSC-sEVs represent a highly promising cell-free platform that may shift the paradigm from hormone replacement to functional regeneration, restoring both endocrine function and fertility in POI patients. - Source: PubMed
Publication date: 2026/08/27
Feng MingxiaSu JiaminYu GuangjiaoWu JuanlingLi YingYang LiLiang TongtongYu LeiZeng ZhaoyangZhao Fenqin